Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most ...

Cardiovascular disease and mental illness commonly co-occur. Addressing them together can improve both mental health and ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...